Home/Rnatics/Thomas F. Frischmuth, PhD

TF

Thomas F. Frischmuth, PhD

CEO, Co-Founder

Therapeutic Areas

Pulmonary & Respiratory Fibrotic Diseases Inflammatory Diseases

Rnatics Pipeline

Drug	Indication	Phase
RCS-21	Acute exacerbations in Idiopathic Pulmonary Fibrosis (IPF)	Phase 1

Leadership Team at Rnatics

Stefan Engelhardt, MD, PhD

CSO, Co-Founder

Klaus F. Rabe, MD

CMO, Co-Founder

Christina Beck, PhD

Project Scientist

Prof. Dr. Thomas Thum

View full Rnatics profile